---
schema_version: "secwatch.filing_event.v1"
accession: "0001770787-24-000007"
form_type: "8-K"
ticker: "TXG"
cik: "0001770787"
company_name: "10x Genomics, Inc."
filed_at: "2024-01-16T23:59:59+00:00"
generated_at: "2026-06-06T23:22:00.045615+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CCO James Wilbur to depart 10x Genomics on Feb 1, 2024; gets severance

## Summary
- James Wilbur, Chief Commercial Officer, leaving effective Feb 1, 2024; no disagreement with management.
- Severance: six months base salary plus one-time COBRA payment of $14,335.
- No 2023 annual performance bonus for Wilbur.
- Departure not related to company's operations, financial statements, or policies.

## SEC filing metadata
- accession: 0001770787-24-000007
- form_type: 8-K
- ticker: TXG
- cik: 0001770787
- company_name: 10x Genomics, Inc.
- filed_at: 2024-01-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770787/000177078724000007/0001770787-24-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770787/000177078724000007/txg-20240115.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001770787-24-000007
- JSON: https://secwatch.observer/filing/0001770787-24-000007.json
- Plain text: https://secwatch.observer/filing/0001770787-24-000007.txt

## Key facts
- Executive change
  James Wilbur departed as Chief Commercial Officer at 10x Genomics, Inc..
  - Action: departed
  - Role: Chief Commercial Officer
  source text: On January 15, 2024, Chief Commercial Officer James Wilbur and 10x Genomics, Inc. (the “Company”) entered into a Transition and Separation Agreement (the “Agreement”) pursuant to which Dr. Wilbur will depart the Company on February 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770787/000177078724000007/0001770787-24-000007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.